Javascript was detected to be disabled. Javascript is required for some functions on this website.

The Institute for Innovation & Valuation in Health Care, InnoValHC, is an independent not-for-profit research organization. It was established by scientists with medical, health economic, and econometric backgrounds, as well as hands-on management experience, to analyse health economic and treatment strategies (see Profile). Learn more about the institute's Purpose and Projects.


Virtual ISPOR Europe 2020

A panel session on the topic "Social Cost Value Analysis: Do we need an alternative health economic evaluation paradigm?" was organized and moderated by Michael Schlander and, furthermore, current research projects (e.g. a multivariate analysis on health technology assessments (HTAs) published by NICE in England and GBA/IQWiG in Germany) were presented online at the Virtual ISPOR Europe 2020 (November 16-19, 2020).

Read more …

Virtual ESMO Congress 2020

Research projects including a comparative analysis on health technology assessment (HTA) outcomes from England, France and Germany, as well as a comprehensive literature review on the development of medical costs were presented online at the Virtual ESMO Congress 2020 (September 19-21, 2020).

Read more …

WZW und HTA: Wie steht es um die Kosten / Nutzenbeurteilung in der Schweiz?

Talk in German available: Michael Schlander presented on the topic "HTA in Switzerland - WZW Criteria" (Wirksamkeit / Efficacy, Zweckmässigkeit / Appropriateness, Wirtschaftlichkeit / Efficiency) at the 6. Swiss Healthcare Day in Bern / Switzerland (January 15, 2020) .

Read more …

HTA Agencies Need Evidence-Informed Deliberative Processes

Epub ahead of print: Most recent publication on "HTA agencies need evidence-informed deliberative processes: Comment on "Use of evidence-informed deliberative processes by health technology assessment agencies around the globe" in the International Journal of Health Policy and Management (online available as of February 19, 2020).

Read more …

Availability, Accessibility and Delivery to Patients of Orphan Medicines approved by the EMA for Hereditary Metabolic Diseases

Now online available: Most recent research article by the MetabERN collaboration group on "Availability, accessibility and delivery to patients of the 28 orphan medicines approved by the European Medicine Agency for hereditary metabolic diseases in the MetabERN network" in the Orphanet Journal of Rare Diseases (online available as of January 06, 2020).

Read more …